Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 24, 2026 | June 26, 2026 |
| Galera Therapeutics, Inc.GRTX · Entity 15899 | Director | July 01, 2023 | July 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23 | Direct | 45,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Galera Therapeutics, Inc.
Report date July 01, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 · Expires 2033-06-30 | Direct | 23,382 |
Reported balance
After 2023-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-01 · Grant · Acquired 23,382 · Balance 23,382 F1: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Person's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Person's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:21 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001628280-26-045780 · wk-form4_1782505258.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 21:23 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 123,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001842952-25-000073 · wk-form4_1749763407.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,500 Underlying: Common Stock · 123,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 12, 2026 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2026 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 11:47 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001842952-24-000044 · wk-form4_1718365616.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:11 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 23,382 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0000950170-23-031628 · ownership.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,382 Underlying: Common Stock · 23,382 shares Expires 2033-06-30 F1 · derivative.exercise_date: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Person's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:15 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-23-015766 · doc4.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 31, 2023 Filed May 31, 2023 20:53 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001842952-23-000061 · wf-form4_168556639644192.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) May 31, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 58,496 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-22-024971 · doc4.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,496 Underlying: Common Stock · 58,496 shares Expires 2032-06-30 F1 · derivative.exercise_date: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000899243-22-022790 · doc4.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:10 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001842952-22-000060 · wf-form4_165428703516071.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: 1.The option vests and becomes exercisable on the earlier of (i) June 2, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:30 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 20,000 | $2.74 | $54,804.00 |
DisclosureSEC source: 0000899243-21-049012 · doc4.xml · nonDerivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.725 to $2.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:16 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 8,730 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000899243-21-027606 · doc4.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,730 Underlying: Common Stock · 8,730 shares Expires 2031-06-30 F1 · derivative.exercise_date: This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:41 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 9,888 | $0.00 Strike: $8.90 | $0.00 |
DisclosureSEC source: 0000899243-21-024505 · doc4.xml · derivative · entry 2 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,888 Underlying: Common Stock · 9,888 shares Expires 2031-06-15 F2 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:41 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 10,000 | $9.13 | $91,300.00 |
DisclosureSEC source: 0000899243-21-024505 · doc4.xml · nonDerivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $9.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 00:13 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 10,000 | $8.65 | $86,511.00 |
DisclosureSEC source: 0000899243-21-022167 · doc4.xml · nonDerivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.49 to $8.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:35 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 10,000 | $8.64 | $86,381.00 |
DisclosureSEC source: 0000899243-21-021576 · doc4.xml · nonDerivative · entry 2 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:35 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 10,000 | $8.64 | $86,410.00 |
DisclosureSEC source: 0000899243-21-021576 · doc4.xml · nonDerivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.6759, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 12:13 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 19,776 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000899243-20-009939 · doc4.xml · derivative · entry 1 West Linda · CIK 0001805257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,776 Underlying: Common Stock · 19,776 shares Expires 2030-03-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six (36) substantially equal monthly installments, such that the option shall be fully vested on March 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.